Biomarkers for depression: recent insights, current challenges and future prospects
- PMID: 28546750
- PMCID: PMC5436791
- DOI: 10.2147/NDT.S114542
Biomarkers for depression: recent insights, current challenges and future prospects
Abstract
A plethora of research has implicated hundreds of putative biomarkers for depression, but has not yet fully elucidated their roles in depressive illness or established what is abnormal in which patients and how biologic information can be used to enhance diagnosis, treatment and prognosis. This lack of progress is partially due to the nature and heterogeneity of depression, in conjunction with methodological heterogeneity within the research literature and the large array of biomarkers with potential, the expression of which often varies according to many factors. We review the available literature, which indicates that markers involved in inflammatory, neurotrophic and metabolic processes, as well as neurotransmitter and neuroendocrine system components, represent highly promising candidates. These may be measured through genetic and epigenetic, transcriptomic and proteomic, metabolomic and neuroimaging assessments. The use of novel approaches and systematic research programs is now required to determine whether, and which, biomarkers can be used to predict response to treatment, stratify patients to specific treatments and develop targets for new interventions. We conclude that there is much promise for reducing the burden of depression through further developing and expanding these research avenues.
Keywords: inflammation; major depressive disorder; mood disorder; personalized medicine; stratification; treatment response.
Conflict of interest statement
Disclosure AHY has in the last 3 years received honoraria for speaking from Astra Zeneca (AZ), Lundbeck, Eli Lilly, Sunovion; honoraria for consulting from Allergan, Livanova and Lundbeck, Sunovion, Janssen; and research grant support from Janssen and UK funding agencies (NIHR, MRC, Wellcome Trust). AJC has in the last 3 years received honoraria for speaking from Astra Zeneca (AZ), honoraria for consulting from Allergan, Livanova and Lundbeck, and research grant support from Lundbeck and UK funding agencies (NIHR, MRC, Wellcome Trust). The authors report no other conflicts of interest in this work.
Figures

Similar articles
-
A review of new insights into existing major depressive disorder biomarkers.Heliyon. 2023 Aug 9;9(8):e18909. doi: 10.1016/j.heliyon.2023.e18909. eCollection 2023 Aug. Heliyon. 2023. PMID: 37664743 Free PMC article. Review.
-
A cross talk on the role of contemporary biomarkers in depression.Biomarkers. 2024 Feb;29(1):18-29. doi: 10.1080/1354750X.2024.2308834. Epub 2024 Jan 31. Biomarkers. 2024. PMID: 38261718 Review.
-
Biomarkers of Major Depressive Disorder: Knowing is Half the Battle.Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):12-25. doi: 10.9758/cpn.2021.19.1.12. Clin Psychopharmacol Neurosci. 2021. PMID: 33508785 Free PMC article. Review.
-
Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.Turk Psikiyatri Derg. 2021;32(4):293-295. doi: 10.5080/u26899. Turk Psikiyatri Derg. 2021. PMID: 34964106 English, Turkish.
-
Brain-derived neurotrophic factor (BDNF) and inflammatory markers: Perspectives for the management of depression.Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;108:110151. doi: 10.1016/j.pnpbp.2020.110151. Epub 2020 Oct 21. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 33096156 Review.
Cited by
-
A comparative study of psychosocial determinants and mental well-being in chronic kidney disease patients: A closer look.Ind Psychiatry J. 2019 Jan-Jun;28(1):63-67. doi: 10.4103/ipj.ipj_23_19. Epub 2019 Dec 11. Ind Psychiatry J. 2019. PMID: 31879449 Free PMC article.
-
Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time.Compr Psychoneuroendocrinol. 2022 Jan 15;10:100116. doi: 10.1016/j.cpnec.2022.100116. eCollection 2022 May. Compr Psychoneuroendocrinol. 2022. PMID: 35774109 Free PMC article.
-
Inflammation as a treatment target in mood disorders: review.BJPsych Open. 2020 Jun 5;6(4):e60. doi: 10.1192/bjo.2020.43. BJPsych Open. 2020. PMID: 32498754 Free PMC article.
-
The Clinical Utility of Biomarkers in Diagnosing Major Depressive Disorder in Adults: A Systematic Review of Literature From 2013 to 2023.Psychiatry Investig. 2025 Apr;22(4):341-356. doi: 10.30773/pi.2024.0152. Epub 2025 Apr 11. Psychiatry Investig. 2025. PMID: 40262783 Free PMC article.
-
Hycanthone Inhibits Inflammasome Activation and Neuroinflammation-Induced Depression-Like Behaviors in Mice.Biomol Ther (Seoul). 2023 Mar 1;31(2):161-167. doi: 10.4062/biomolther.2022.073. Epub 2022 Oct 7. Biomol Ther (Seoul). 2023. PMID: 36203404 Free PMC article.
References
-
- Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859–877. - PubMed
-
- Kingdon D, Wykes T. Increased funding needed for mental health research. BMJ. 2013;346:f402. - PubMed
-
- Vivekanantham S, Strawbridge R, Rampuri R, Ragunathan T, Young AH. Parity of publication for psychiatry. Br J Psychiatry. 2016;209(3):257–261. - PubMed
-
- Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–659. - PubMed
-
- Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–751. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical